Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.7.3233

Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia  

Sipetic-Grujicic, Sandra Branko (Institute of Epidemiology, Faculty of Medicine, Belgrade University)
Murtezani, Zafir Hajdar (Clinical Hospital Centre Bezanijska Kosa)
Neskovic-Konstatinovic, Zora Borivoje (Institute for Oncology and Radiology of Serbia)
Marinkovic, Jelena Milutin (Institute of Medical Statistics and Informatics, Faculty of Medicine, Belgrade University)
Kovcin, Vladimir Nikola (Clinical Hospital Centre Bezanijska Kosa)
Andric, Zoran Gojko (Clinical Hospital Centre Bezanijska Kosa)
Kostic, Sanja Vladeta (Clinical Hospital Centre Bezanijska Kosa)
Ratkov, Isidora Stojan (Institute of Epidemiology, Faculty of Medicine, Belgrade University)
Maksimovic, Jadranka Milutin (Institute of Epidemiology, Faculty of Medicine, Belgrade University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.7, 2014 , pp. 3233-3238 More about this Journal
Abstract
Background: The aim of this study was to analyze the demographic and clinical characteristics of male breast cancer patients in Serbia, and furthermore to determine overall survival and predictive factors for prognosis. Materials and Methods: In the period of 1996-2006 histopathological diagnosis of breast cancer was made in 84 males at the Institute for Oncology and Radiology of Serbia. For statistical analyses the Kaplan-Meier method, long-rank test and Cox proportional hazards regression model were used. Results: The mean age at diagnosis with breast cancer was $64.3{\pm}10.5$ years with a range from 35-84 years. Nearly 80% of the tumors showed ductal histology. About 44% had early tumor stages (I and II) whereas 46.4% and 9.5% of the male exhibitied stages III and IV, respectively. Only 7.1% of male patients were grade one. One-fifth of all patients had tumors measuring ${\leq}2cm$, and 14.3% larger than 5 cm. Lymph node metastasis was recorded in 40.4% patients and 47% relapse. Estrogen and progesterone receptor expression was positive in 66.7% and 58.3%, respectively. Among 14.3% of individuals tumor was HER2 positive. About two-thirds of all male patients had radical mastectomy (66.7%). Adjuvant hormonal (tamoxifene), systematic chemotherapy (CMF or FAC) and adjuvant radiotherapy were given to 59.5%, 35.7% and 29.8% patients respectively. Overall survival rates at five and ten years for male breast cancer were 55.0% and 43.9%, respectively. According to the multivariate Cox regression predictive model, a lower initial disease stage, a lower tumor grade, application of adjuvant hormone therapy and no relapse occurrence were significant independent predictors for good overall survival. Conclusions: Results of the treatment would be better if disease is discovered earlier and therefore health education and screening are an imperative in solving this problem.
Keywords
Breast cancer; men; survival analysis; predictors;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Volkers N (1999). In coping with cancer, gender metters. J Natl Canver Inst, 91, 1712-4.   DOI
2 Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne DW (1978). Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg, 188, 60-5.   DOI
3 Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7.   DOI   ScienceOn
4 Giordano SH, Perkins GH, Broglio K, et al (2005). Adjuvant systemic therapy for male breast carcinoma. Cancer, 104, 2359-64.   DOI   ScienceOn
5 Guinee VF, Olsson H, Moller T, et al (1993). The prognosis of breast cancer in males. A report of 335 cases. Cancer, 71, 154-61.   DOI
6 Joshi MG, Lee AK, Loda M, et al (1996). Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer, 77, 490-8.   DOI
7 Lanitis S, Rice AJ, Vaughan A, et al (2008). Diagnosis and management of male breast cancer. World J Surg, 32, 2471-6.   DOI
8 Mustafa IA, Cole B, Wanebo HJ, Bland KI, Chang HR (1998). Prognostic analysis of survival in small breast cancers. J Am Coll Surg, 186, 562-9.   DOI   ScienceOn
9 Mahdi KM, Nassiri MR, Nasiri K (2013). Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev, 14, 3403-9.   과학기술학회마을   DOI   ScienceOn
10 Nahleh ZA, Srikantiah R, Safa M, et al (2007). Male breast cancer in the veterans affairs population: a comparative analysis. Cancer, 109, 1471-7.   DOI   ScienceOn
11 D'Avanzo B, La Vecchia C (1995). Risk factors for male breast cancer. Br J Cancer, 71, 1359-62.   DOI   ScienceOn
12 Cimmino VM, Degnim AC, Sabel MS, et al (2004). Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol, 86, 74-7.   DOI   ScienceOn
13 Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H (2008). Male breast cancer: is the scenario changing. World J Surg Oncol, 6, 58-69.   DOI   ScienceOn
14 De Perrot M, Deleaval J, Robert J, Spiliopoulos A (2000). Thirty-year experience of surgery for breast carcinoma in men. Eur J Surg, 166, 929-31.   DOI   ScienceOn
15 Foerster R, Foerster FG, Wulff V, et al (2011). Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer, 11, 335-43.   DOI
16 Fentiman IS, Fourquet A, Hortobagyi GN (2006). Male breast cancer. Lancet, 367, 595-604.   DOI   ScienceOn
17 Goldhirsch A, Wood WC, Coates AS, et al (2011). Panel members. Expert consensus on the primary therapy of early breast cancer. Ann Oncol, 22, 1736-47.   DOI   ScienceOn
18 Goss PE, Reid C, Pintilie M, Lim R, Miller N (1999). Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years:1955-1996. Cancer, 85, 629-39.   DOI
19 Gomes-Raposo C, Zambrana Tevar F, Sereno Moyano M, Lopez Gomez M, Casado E (2010). Male breast cancer. Cancer Treat Rev, 36, 451-7.   DOI   ScienceOn
20 Agrawal A, Ayantunde A, Rampaul R, Robertson R (2007). Male breast cancer: a review of clinical management. Breast Cancer Res Treat, 103, 11-21.   DOI
21 Ahmadian M, Samah AA (2013). Application of health behavior theories to breast cancer screening among Asian women. Asian Pac J Cancer Prev, 14, 4005-13.   과학기술학회마을   DOI   ScienceOn
22 Auvien A, Curtis RE, Ron E (2002). Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst, 94, 1330-2.   DOI   ScienceOn
23 Berg JW, Hutter RV (1995). Breast cancer. Cancer, 75, 257-69.   DOI
24 Bergmann A, Bello MA, Andrade Costa CR, et al (2012). Male breast cancer: overall survival in a single institution. J Clin Oncol, 30, 93.
25 Vaizey C, Burke M, Lange M (1999). Carcinoma of the male breast - a review of 91 patients from the Johannesburg Hospital breast clinics. S Afr J Surg, 37, 6-8.
26 Weiss JR, Moysich KB, Swede H (2005). Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 20-6.
27 Wolff AC, Hammond ME, Schwartz JN, et al. (2007). American society of clinical oncology/college of American pathologistsguideline recommendations for human growt factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.
28 Yildirim E, Berberoglu U (1998). Male breast cancer: a 22-year experience. Eur J Surg Oncol, 24, 548-52.   DOI   ScienceOn
29 Ros JS, Fletcher JA, Linette GP, et al (2003). The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. The Oncologist, 8, 307-25.   DOI   ScienceOn
30 Omer Fatih Olmez OF, Evrensel T, Cubukcu E, et al (2013). Prognostic significance of human epidermal receptor (HER)- 3 immunohistochemical expression in patients with metastatic breast cancer. Asian Pac J Cancer Prev, 14, 4115-9.   과학기술학회마을   DOI   ScienceOn
31 Ravandi-Kashani F, Hayes TG (1998). Male breast cancer: a review of the literature. Eur J Cancer, 34, 1341-7.   DOI   ScienceOn
32 Ribeiro G, Swindell R (1992). Adjuvant tamoxifen for male breast cancer. Br J Cancer, 65, 252-4.   DOI   ScienceOn
33 Salvadori B, Saccozzi R, Manzari A, et al (1994). Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer, 30, 930-5.   DOI   ScienceOn
34 Sasco AJ, Lowenfels AB, Pasker-de Jong P (1993). Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer, 53, 538-49.   DOI   ScienceOn
35 Slamon D, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.   DOI   ScienceOn
36 Schaub NP, Maloney N, Schneider H, Feliberti E, Perry R (2008). Changes in male breast cancer over a 30-year period. Am Surg, 74, 707-12.
37 Talluri S, Kakarala R, Karedan T, Kakarala M (2011). Male breast carcinoma in United States: survival rate and determinants of prognosis. J Clin Oncol, 29, 32.   DOI   ScienceOn
38 Thompson D, Duedal S, Kirner J, et al (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst, 97, 813-22.   DOI   ScienceOn
39 Bruce DM, Heyes SD, Payne S (1996). Male breast cancer: clinicopathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol, 22, 42-6.   DOI   ScienceOn
40 Xu CY, Jiang ZN, Zhou Y, Li JJ, Huang LM (2013). Estrogen receptor $\alpha$ roles in breast cancer chemoresistance. Asian Pac J Cancer Prev, 14, 4049-52.   과학기술학회마을   DOI   ScienceOn
41 Early Breast Cancer Trialist Collaborative group (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet, 365, 1687-717.   DOI   ScienceOn